Celcuity shares climbed 6.6% in afternoon trading as investors increased exposure ahead of a critical regulatory milestone: the U.S. Food and Drug Administration's decision on gedatolisib, the company's lead oncology candidate, scheduled for July 17, 2026 - just three days away.
The company's New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer was accepted into the FDA's Real-Time Oncology Review program and was granted Priority Review status, signaling the agency's recognition of the drug's potential relevance to a serious unmet medical need. In addition, gedatolisib has been awarded both Breakthrough Therapy and Fast Track designations.
Regulatory momentum is complemented by clinical data. The Phase 3 VIKTORIA-1 trial met its primary endpoint, delivering a statistically significant and clinically meaningful improvement in progression-free survival, according to the information released by the company. Management has described commercial launch preparations as nearly complete, with a mid-July approval targeted if the FDA decision is favorable.
Market participants have interpreted these elements as increasing the probability that Celcuity could recognize its first-ever product revenues in the second half of 2026. That prospect appears to be a key driver behind the recent buying activity in the stock.
Broader market conditions offered a supporting backdrop. The NASDAQ composite advanced 0.9% on the day, a move that often lifts investor sentiment across growth-oriented and clinical-stage biotechnology names. On the sell-side, the consensus view remains strongly positive: nine analysts continue to carry a "Strong Buy" average rating on the shares, a stance that can reduce resistance for new buyers entering the market in the run-up to a binary regulatory event.
Volatility has been pronounced as the deadline approaches. The shares traded in a wide intraday range, touching a low of $101.09 before reaching a high of $113.32, reflecting the heightened trading activity typical for biotech stocks when a major FDA decision is imminent.
Context for investors
With the FDA decision just days away, the confluence of expedited regulatory pathways, positive Phase 3 data, near-ready commercial preparations, and an encouraging analyst consensus appears to be the principal force behind the recent price action in Celcuity stock.